Elsevier

Neuropharmacology

Volume 35, Issue 1, January 1996, Pages 23-28
Neuropharmacology

Systemic dl-Kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats

https://doi.org/10.1016/0028-3908(95)00145-XGet rights and content

Abstract

Kynurenine (KYN) is the precursor of kynurenic acid (KYNA), an endogenous antagonist of the glycine site of the NMDA (N-methyl-D-aspartate) receptor. Probenecid (PROB), blocks the excretion of KYNA from the extracellular fluid. KYNA antagonizes the toxic action of quinolinic acid (QUIN), an endogenous NMDA receptor agonist. In this study, we tested the effect of the systemic administration of KYN and PROB, either alone or in combination, on QUIN-induced circling behavior and γ-aminobutyric acid (GABA) depletion in rats. Circling behavior and GABA depletion induced by QUIN were both partially prevented by PROB (200 and 300 mg/kg) and KYN (300 and 450 mg/kg) treatments. Lower doses of drugs administered separately were nonprotective. However, when administered in combination, doses of 150 or 300 mg/kg KYN plus 100 mg/kg PROB significantly protected animals against QUIN neurotoxicity. These findings suggest a role of KYN and PROB as promoters of KYNA-mediated NMDA receptor antagonism, via an increase of kynurenate in brain extracellular spaces.

References (48)

  • A.B. Norman et al.

    Sensitization of rotation behavior in rats with unilateral 6-hydroxydopamine or kainic acid-induced striatal lesions

    Pharmac. Biochem. Behav.

    (1990)
  • P. Russi et al.

    Indolpyruvic acid administration increases the brain content of kynurenic acid

    Biochem. Pharmac.

    (1989)
  • A. Santamaría et al.

    MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum

    Neurosci. Lett.

    (1993)
  • R. Schwarcz et al.

    Rotational behavior in rats with unilateral striatal kainic acid lesions: a behavioral model for studies on intact dopamine receptors

    Brain Res.

    (1979)
  • R. Schwarcz et al.

    Excitotoxic models for neurodegenerative disorders

    Life Sci.

    (1984)
  • T.W. Stone et al.

    Quinolinic acid and other kynurenines in the central nervous system

    Neuroscience

    (1985)
  • Z. Susel et al.

    Behavioral evaluation of the anti-excitotoxic properties of MK-801: comparison with neurochemical measurements

    Neurosci. Lett.

    (1989)
  • C.P. Taylor et al.

    Probenecid pretreatment enhances anticonvulsant action of NBQX in mice

    Eur. J. Pharmac.

    (1992)
  • L. Vécsei et al.

    Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain

    Brain Res. Bull.

    (1992)
  • M.F. Beal et al.

    Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

    Nature

    (1986)
  • J.T. Coyle et al.

    Oxidative stress, glutamate and neurodegenerative disorders

    Science

    (1993)
  • A.C. Foster et al.

    MK-801 prevents degeneration of striatal neurones caused by intrastriatal injection of quinolinic acid

  • A.C. Foster et al.

    Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation

    J. Neurosci.

    (1988)
  • S. Fukui et al.

    Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism

    J. Neurochem.

    (1991)
  • Cited by (53)

    • Deficiency of kynurenine 3-monooxygenase exacerbates impairment of prepulse inhibition induced by phencyclidine

      2022, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      Administration of KYN significantly increased 3-HK, but not KA, levels in the PFC and HIP of mice (Fig. 4D). When KYN was co-administered with probenecid, which increases endogenous KA by inhibiting the efflux of KA [23,24], the attenuative effect of KYN on PPI impairment was diminished (Fig. 4J). The present doses of KYN metabolites i.c.v. induce seizures in rodents [35].

    • Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo

      2021, EBioMedicine
      Citation Excerpt :

      D-kynurenine contributes to kynurenine derivatives independent of kynureninase such as kynurenic acid, but these are not associated with toxicity. In fact, kynurenic acid even has neuroprotective properties [15,18], and kynureninase inhibition is a neuroprotective treatment strategy to shunt kynurenine metabolites away from quinolinic acid to kynurenic acid [19,20]. Under these assumptions, D-kynurenine could potentially be a therapeutically interesting immunosuppressive metabolite.

    • Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine

      2015, Neuroscience
      Citation Excerpt :

      The increase in kynurenic acid is associated with an inhibition of CNS function, such as the suppression of allodynia and chronic pain (Pineda-Farias et al., 2013), seizures (Nemeth et al., 2004) and reduced abilities in learning and other cognitive tasks (Alexander et al., 2013; Chess et al., 2007, 2009; Pershing et al., 2015; Pocivavsek et al., 2012, 2014; Shepard et al., 2003; Nilsson et al., 2006). In several studies, increased kynurenic acid has been shown to be protective against damage induced by ischemia (Sas et al., 2008; Robotka et al., 2008) or toxins such as 6-hydroxydopamine (Silva-Adaya et al., 2011), amyloid-β (Carrillo-Mora et al., 2010) and quinolinic acid (Santamaria et al., 1996; Harris et al., 1998). The concentrations that can be achieved by either kynurenine administration or KMO inhibition are 10–100 times greater than those measured in normal mammalian tissue but are likely to be relevant in pathological conditions where CNS involvement occurs and where behavioral aberrations are problematic, especially when KMO activity is itself compromised.

    View all citing articles on Scopus
    View full text